PROBLEM
The loss of CAR-T in blood is a problem for oncologists making them more difficult to personalize the treatment.
SOLUTION
Molecular imaging is a non-invasive solution for providing information about CAR-T therapy to oncologists.
TECHNOLOGY
PET radiotracers are contrast agents that allow molecular imaging using a medical PET scanner.
What are radiotracers?
Radiotracers are compounds that combine the precision of specific binding molecules (ligand) with the radioactive properties of isotopes.
Radiotracers consists of three parts:
– Ligand that functions as a specific carrier.
– Isotope gives radiodiagnostic applications.
– Linker that binds the ligand to the isotope.
Radiotracers are a crucial element for personalized nuclear medicine and precision oncology.
YSOTOPE designs new targeted radiotracers for monitoring CAR-T cells.
YSOTOPE designs new targeted radiotracers for monitoring CAR-T cells.
OUR APPROACH
YSOTOPE uses specific ligands to design co-diagnostic radiotracers to monitor CAR-T cells inside the patient’s body.
Using nuclear imaging YSOTOPE’s radiotracers provide information about CAR-T treatment:
- Distribution of CAR-T cells in different tissues.
- Concentration of CAR-T cells with quantitative information.
YSOTOPE radiotracer provides high-value information about CAR-T treatment.
YSOTOPE uses specific ligands to design co-diagnostic radiotracers to monitor CAR-T cells inside the patient’s body.
Using nuclear imaging YSOTOPE’s radiotracers provide information about CAR-T treatment:
- Distribution of CAR-T cells in different tissues.
- Concentration of CAR-T cells with quantitative information.
OUR STRATEGY
DEVELOPMENT
Co-development through partnerships in R&D projects.
VALIDATION
Test the radiopharmaceutical in animals and humans.
PROTECTION
Ensure assets exclusivity by combining different IPR tools.
MONETIZATION
Patents monetization through IP licensing and sublicensing.
LABELING
4 Months
Molecule and isotope conjugation
IN-VITRO
6 Months
Affinity and metabolism studies
IN-VIVO
6 Months
Preclinical studies in animals
TOXICITY
soon
Toxicity and biodistribution studies
CLINICAL TRIALS
soon
Clinical studies in humans
ABOUT US
YSOTOPE is a Spanish company founded in 2022 by a team with experience in deep tech entrepreneurship and radiochemistry.
YSOTOPE is a Spanish company founded in 2022 by a team with experience in deeptech entrepreneurship and radiochemistry. 
YSOTOPE is also counting on expert entities as strategic support YSOTOPE is also counting on expert entities as strategic support.
Scientific
Business
CONTACT
Contact
REFERENCES:
Icons: https://www.flaticon.com/
Background images: https://unsplash.com/
Radiopharmaceutical diagram: https://smart.servier.com/
Affinity and metabolism & Preclinical studies images: https://app.biorender.com/